BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 23666966)

  • 21. KAI1 expression in thyroid neoplasms: its linkage with clinicopathologic features in papillary carcinoma.
    Ito Y; Yoshida H; Uruno T; Nakano K; Takamura Y; Miya A; Kobayashi K; Yokozawa T; Matsuzuka F; Kuma K; Miyauchi A
    Pathol Res Pract; 2003; 199(2):79-83. PubMed ID: 12747469
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
    Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
    Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Down-regulation of an inhibitor of cell growth, transmembrane protein 34 (TMEM34), in anaplastic thyroid cancer.
    Akaishi J; Onda M; Okamoto J; Miyamoto S; Nagahama M; Ito K; Yoshida A; Shimizu K
    J Cancer Res Clin Oncol; 2007 Apr; 133(4):213-8. PubMed ID: 17072649
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Distinct patterns of E-cadherin CpG island methylation in papillary, follicular, Hurthle's cell, and poorly differentiated human thyroid carcinoma.
    Graff JR; Greenberg VE; Herman JG; Westra WH; Boghaert ER; Ain KB; Saji M; Zeiger MA; Zimmer SG; Baylin SB
    Cancer Res; 1998 May; 58(10):2063-6. PubMed ID: 9605742
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PATZ1 acts as a tumor suppressor in thyroid cancer via targeting p53-dependent genes involved in EMT and cell migration.
    Chiappetta G; Valentino T; Vitiello M; Pasquinelli R; Monaco M; Palma G; Sepe R; Luciano A; Pallante P; Palmieri D; Aiello C; Rea D; Losito SN; Arra C; Fusco A; Fedele M
    Oncotarget; 2015 Mar; 6(7):5310-23. PubMed ID: 25595894
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Frequent silencing of RASSF1A via promoter methylation in follicular thyroid hyperplasia: a potential early epigenetic susceptibility event in thyroid carcinogenesis.
    Brown TC; Juhlin CC; Healy JM; Prasad ML; Korah R; Carling T
    JAMA Surg; 2014 Nov; 149(11):1146-52. PubMed ID: 25229773
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression of the melanoma-associated antigen is associated with progression of human thyroid cancer.
    Cheng S; Liu W; Mercado M; Ezzat S; Asa SL
    Endocr Relat Cancer; 2009 Jun; 16(2):455-66. PubMed ID: 19261683
    [TBL] [Abstract][Full Text] [Related]  

  • 28. RTN4IP1 is down-regulated in thyroid cancer and has tumor-suppressive function.
    Rahbari R; Kitano M; Zhang L; Bommareddi S; Kebebew E
    J Clin Endocrinol Metab; 2013 Mar; 98(3):E446-54. PubMed ID: 23393170
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reduced E-cadherin expression contributes to the loss of p27kip1-mediated mechanism of contact inhibition in thyroid anaplastic carcinomas.
    Motti ML; Califano D; Baldassarre G; Celetti A; Merolla F; Forzati F; Napolitano M; Tavernise B; Fusco A; Viglietto G
    Carcinogenesis; 2005 Jun; 26(6):1021-34. PubMed ID: 15718252
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Patterns of expression of cell cycle/apoptosis genes along the spectrum of thyroid carcinoma progression.
    Saltman B; Singh B; Hedvat CV; Wreesmann VB; Ghossein R
    Surgery; 2006 Dec; 140(6):899-905; discussion 905-6. PubMed ID: 17188136
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Silencing of homeobox B9 is associated with down-regulation of CD56 and extrathyroidal extension of tumor in papillary thyroid carcinoma.
    Kim JH; Kim YH; Han JH; Lee KB; Sheen SS; Lee J; Soh EY; Park TJ
    Hum Pathol; 2012 Aug; 43(8):1221-8. PubMed ID: 22225776
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The helix-loop-helix protein, Id-1, is overexpressed and regulates growth in papillary thyroid cancer.
    Kebebew E; Treseler PA; Duh QY; Clark OH
    Surgery; 2003 Aug; 134(2):235-41. PubMed ID: 12947323
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Frizzled-1 is down-regulated in follicular thyroid tumours and modulates growth and invasiveness.
    Ulivieri A; Lavra L; Dominici R; Giacomelli L; Brunetti E; Sciacca L; Trovato M; Barresi G; Foukakis T; Jia-Jing L; Larsson C; Bartolazzi A; Sciacchitano S
    J Pathol; 2008 May; 215(1):87-96. PubMed ID: 18306168
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tissue inhibitor of metalloproteinases-1 (TIMP-1) mRNA is elevated in advanced stages of thyroid carcinoma.
    Shi Y; Parhar RS; Zou M; Hammami MM; Akhtar M; Lum ZP; Farid NR; Al-Sedairy ST; Paterson MC
    Br J Cancer; 1999 Mar; 79(7-8):1234-9. PubMed ID: 10098765
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of survivin in thyroid tumors: differences of expression in well-differentiated, non-well-differentiated, and anaplastic thyroid cancers.
    Pannone G; Santoro A; Pasquali D; Zamparese R; Mattoni M; Russo G; Landriscina M; Piscazzi A; Toti P; Cignarelli M; Lo Muzio L; Bufo P
    Thyroid; 2014 Mar; 24(3):511-9. PubMed ID: 24117205
    [TBL] [Abstract][Full Text] [Related]  

  • 36. miR-191 down-regulation plays a role in thyroid follicular tumors through CDK6 targeting.
    Colamaio M; Borbone E; Russo L; Bianco M; Federico A; Califano D; Chiappetta G; Pallante P; Troncone G; Battista S; Fusco A
    J Clin Endocrinol Metab; 2011 Dec; 96(12):E1915-24. PubMed ID: 21956418
    [TBL] [Abstract][Full Text] [Related]  

  • 37. DRO1 inactivation drives colorectal carcinogenesis in ApcMin/+ mice.
    Grill JI; Neumann J; Herbst A; Hiltwein F; Ofner A; Marschall MK; Wolf E; Kirchner T; Göke B; Schneider MR; Kolligs FT
    Mol Cancer Res; 2014 Nov; 12(11):1655-62. PubMed ID: 25053805
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunohistochemical analysis of p27/kip1 expression in thyroid carcinoma.
    Resnick MB; Schacter P; Finkelstein Y; Kellner Y; Cohen O
    Mod Pathol; 1998 Aug; 11(8):735-9. PubMed ID: 9720501
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SIN1, a critical component of the mTOR-Rictor complex, is overexpressed and associated with AKT activation in medullary and aggressive papillary thyroid carcinomas.
    Moraitis D; Karanikou M; Liakou C; Dimas K; Tzimas G; Tseleni-Balafouta S; Patsouris E; Rassidakis GZ; Kouvaraki MA
    Surgery; 2014 Dec; 156(6):1542-8; discussion 1548-9. PubMed ID: 25456951
    [TBL] [Abstract][Full Text] [Related]  

  • 40. E-cadherin: a differentiation marker in thyroid malignancies.
    Brabant G; Hoang-Vu C; Cetin Y; Dralle H; Scheumann G; Mölne J; Hansson G; Jansson S; Ericson LE; Nilsson M
    Cancer Res; 1993 Oct; 53(20):4987-93. PubMed ID: 8402689
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.